A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma

NCT01320085 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

183

Enrollment

INDUSTRY

Sponsor class

Conditions

BRAF or NRAS Mutant Metastatic Melanoma

Interventions

DRUG: MEK162

Sponsor

Pfizer